Skip to main content

natalizumab

Generic: natalizumab·Brand: Tysabri

natalizumab: 3 clinical trials tracked.

natalizumab evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about natalizumab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trials (3)

Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

NCT05658497·BIIB
Recruiting

Primary endpoint: Number of Major Congenital Malformations (MCMs)

Observational908 targetStarted 2023-10Completion 2032-078 sites · Australia, Germany, Ireland, Spain…Biogen

A Pilot Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

NCT05618301·Phase 1
Completed

Primary endpoint: Safety and tolerability as assessed by the incidence of dose-limiting toxicities (DLTs)

Interventionalopen10 enrolledStarted 2023-07Completion 2025-061 site · United StatesWashington University School of Medicine

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

NCT05688436·BIIB
Active, not recruiting

Primary endpoint: Number of Major Congenital Malformations (MCMs)

Observational1,178 targetStarted 2021-09Completion 2031-011 site · United StatesBiogen